ES2184069T3 - Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace. - Google Patents
Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace.Info
- Publication number
- ES2184069T3 ES2184069T3 ES97912674T ES97912674T ES2184069T3 ES 2184069 T3 ES2184069 T3 ES 2184069T3 ES 97912674 T ES97912674 T ES 97912674T ES 97912674 T ES97912674 T ES 97912674T ES 2184069 T3 ES2184069 T3 ES 2184069T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitors
- tace
- matrix
- insistration
- chr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE AL DESCUBRIMIENTO DE NUEVOS INHIBIDORES NO PEPTIDICOS, DE BAJO PESO MOLECULAR, DE LAS METALOPROTEINASAS DE LA MATRIZ (P.EJ. GELATINASAS, ESTROMELISINAS Y COLAGENASAS) Y DE LA ENZIMA CONVERTIDORA DE TNF- AL (TACE, ENIMA CONVERTIDORA DEL FACTOR- AL DE NECROSIS TUMORAL), LOS CUALES SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES EN LAS CUALES ESTAN IMPLICADAS DICHAS ENZIMAS, COMO ARTRITIS, CRECIMIENTO TUMORAL Y METASTASIS, ANGIOGENESIS, ULCERACION TISULAR, CICATRIZACION ANORMAL DE UNA HERIDA, ENFERMEDAD PERIODONTAL, ENFERMEDAD OSEA, PROTEINURIA, ANEURISMA AORTICO, PERDIDA DE CARTILAGO DEGENERATIVA RESULTANTE DE UNA LESION ARTICULAR TRAUMATICA, ENFERMEDADES DESMIELINIZANTES DEL SISTEMA NERVIOSO CENTRAL, RECHAZO DE INJERTOS, CAQUEXIA, ANOREXIA, INFLAMACION, FIEBRE, RESISTENCIA A INSULINA, CHOQUE SEPTICO, INSUFICIENCIA CARDIACA CONGESTIVA, ENFERMEDAD INFLAMATORIA DEL SISTEMA NERVIOSO CENTRAL, SINDROME DEL COLON IRRITABLE, INFECCION POR VIH, DEGENERACION MACULAR RELACIONADA CON LA EDAD, RETINOPATIA DIABETICA, VITREORRETINOPATIA DIABETICA, RETINOPATIA DE PREMATURIDAD, INFLAMACION OCULAR, QUERATOCONO, SINDROME DE SJOGREN, MIOPIA, TUMORES OCULARES, ANGIOGENESIS/NEOVASCULARIZACION OCULAR. LOS ACIDOS ORTOSULFONAMIDO HIDROXAMICOS DE LA PRESENTE INVENCION, INHIBIDORES DE TACE Y MMP, SE REPRESENTAN MEDIANTE LA FORMULA (1), DONDE LA FRACCION DE ACIDO HIDROXAMICO Y LA FRACCION SULFONAMIDO ESTAN UNIDAS A LOS CARBONOS ADYACENTES DEL GRUPO A, DONDE: A ES UN ANILLO HETEROCICLICO NO AROMATICO MONOCICLICO, DE 5 A 7 MIEMBROS, QUE TIENE DE 1 A 2 HETEROATOMOS SELECCIONADOS INDEPENDIENTEMENTE A PARTIR DE N, O Y S, OPCIONALMENTE SUSTITUIDO POR R 1 , R 2 , R 3 , Y R 4 ; UN CICLOALQUILO C 3 - C 7 QUE CONTIENE 0-2 ENLACES DOBLES Y SUSTITUIDO OPCIONALMENTE POR R 1 , R 2 , R 3 Y R 4 ; O - CHR 5 = CHR 6 -; Y Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 Y R 9 SE DESCRIBEN EN LA DESCRIPCION. SE INCLUYEN ASIMISMO LAS SALES FARMACEUTICAMENTE ACEPTABLES DE DICHOS COMPUESTOS, Y SUS ISOMEROS OPTICOS O DIASTEREOMEROS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72935996A | 1996-10-16 | 1996-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2184069T3 true ES2184069T3 (es) | 2003-04-01 |
Family
ID=24930685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97912674T Expired - Lifetime ES2184069T3 (es) | 1996-10-16 | 1997-10-08 | Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0934259B1 (es) |
JP (1) | JP2001502326A (es) |
KR (1) | KR20000049198A (es) |
CN (1) | CN1105101C (es) |
AR (1) | AR008676A1 (es) |
AT (1) | ATE224364T1 (es) |
AU (1) | AU736134B2 (es) |
BR (1) | BR9712524A (es) |
CA (1) | CA2268895A1 (es) |
DE (1) | DE69715647T2 (es) |
DK (1) | DK0934259T3 (es) |
ES (1) | ES2184069T3 (es) |
HK (1) | HK1020720A1 (es) |
IL (1) | IL129149A (es) |
NZ (1) | NZ335053A (es) |
PT (1) | PT934259E (es) |
WO (1) | WO1998016506A1 (es) |
ZA (1) | ZA979236B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0952148B1 (en) * | 1998-04-10 | 2004-05-12 | Pfizer Products Inc. | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives |
JP2002518368A (ja) | 1998-06-17 | 2002-06-25 | デュポン ファーマシューティカルズ カンパニー | メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類 |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
AU2320500A (en) * | 1999-02-02 | 2000-08-25 | Shionogi & Co., Ltd. | Sulfonamide derivatives having cyclic structures |
MXPA02011570A (es) * | 2000-05-23 | 2004-09-09 | Osmonics Inc | Polimeros de sulfonamida modificados. |
CA2464727A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
US8129406B2 (en) | 2004-03-22 | 2012-03-06 | Southern Research Institute | Nonpeptide inhibitors of matrix metalloproteinases |
FR2947270B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
WO2017117130A1 (en) | 2015-12-28 | 2017-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
JP2022512584A (ja) | 2018-10-04 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 角皮症を処置するためのegfrインヒビター |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
CA2160139A1 (en) * | 1993-04-07 | 1994-10-13 | Richard Edward Galardy | Synthetic matrix metalloprotease inhibitors and uses thereof |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
-
1997
- 1997-10-08 EP EP97912674A patent/EP0934259B1/en not_active Expired - Lifetime
- 1997-10-08 IL IL12914997A patent/IL129149A/xx not_active IP Right Cessation
- 1997-10-08 AU AU49790/97A patent/AU736134B2/en not_active Ceased
- 1997-10-08 KR KR1019990703296A patent/KR20000049198A/ko active IP Right Grant
- 1997-10-08 JP JP10518424A patent/JP2001502326A/ja not_active Ceased
- 1997-10-08 AT AT97912674T patent/ATE224364T1/de not_active IP Right Cessation
- 1997-10-08 BR BR9712524-5A patent/BR9712524A/pt not_active Application Discontinuation
- 1997-10-08 DE DE69715647T patent/DE69715647T2/de not_active Expired - Fee Related
- 1997-10-08 NZ NZ335053A patent/NZ335053A/xx unknown
- 1997-10-08 WO PCT/US1997/018170 patent/WO1998016506A1/en active IP Right Grant
- 1997-10-08 CA CA002268895A patent/CA2268895A1/en not_active Abandoned
- 1997-10-08 CN CN97180606A patent/CN1105101C/zh not_active Expired - Fee Related
- 1997-10-08 ES ES97912674T patent/ES2184069T3/es not_active Expired - Lifetime
- 1997-10-08 DK DK97912674T patent/DK0934259T3/da active
- 1997-10-08 PT PT97912674T patent/PT934259E/pt unknown
- 1997-10-15 AR ARP970104748A patent/AR008676A1/es not_active Application Discontinuation
- 1997-10-15 ZA ZA9709236A patent/ZA979236B/xx unknown
-
1999
- 1999-12-11 HK HK99105839A patent/HK1020720A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20000049198A (ko) | 2000-07-25 |
CN1240424A (zh) | 2000-01-05 |
PT934259E (pt) | 2003-01-31 |
DE69715647T2 (de) | 2003-02-20 |
CA2268895A1 (en) | 1998-04-23 |
ATE224364T1 (de) | 2002-10-15 |
AR008676A1 (es) | 2000-02-09 |
DK0934259T3 (da) | 2003-01-27 |
IL129149A0 (en) | 2000-02-17 |
ZA979236B (en) | 1999-07-15 |
DE69715647D1 (en) | 2002-10-24 |
EP0934259A1 (en) | 1999-08-11 |
AU736134B2 (en) | 2001-07-26 |
NZ335053A (en) | 2000-10-27 |
HK1020720A1 (en) | 2000-05-19 |
EP0934259B1 (en) | 2002-09-18 |
WO1998016506A1 (en) | 1998-04-23 |
AU4979097A (en) | 1998-05-11 |
JP2001502326A (ja) | 2001-02-20 |
CN1105101C (zh) | 2003-04-09 |
IL129149A (en) | 2003-10-31 |
BR9712524A (pt) | 1999-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2184069T3 (es) | Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace. | |
ES2166102T3 (es) | Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace. | |
AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
AR008677A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos como inhibidores de la metalproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos y composicion farmaceutica que los contiene | |
DK2720693T3 (en) | CHROMAN-LIKE CYCLIC PRENYLFLAVONOIDS FOR MEDICAL INTERVENTION IN NEUROLOGICAL DISEASES | |
AR021799A1 (es) | Naftopiranos ciclados en c5-6, su preparacion y composiciones y matrices de (co) polimero que las contienen | |
ES2184070T3 (es) | Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina. | |
ES2011210T3 (es) | Derivados de gem-difosfonato substituido, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AR067762A1 (es) | Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma | |
ES2152444T3 (es) | Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos. | |
ES2061077T3 (es) | Metodo para producir un producto intermedio para la preparacion de promedicamentos. | |
TR200000673T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
TR200000670T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
ES2107212T3 (es) | Derivados de 1,4-benzoxazina como abridores de los canales de potasio. | |
UY23537A1 (es) | Benzopirano y antagonistas de ltb4 relacionados | |
NO20050612L (no) | Pyrrolidinderivater som oksytocinantagonister | |
MX9306528A (es) | Derivados de sulfonamida de compuestos anulares de cicloalquilo-heterociclico substituidos con hidroxi, de benceno fundido. | |
GT200100209A (es) | Derivados puente de piperazina. | |
Wei et al. | Salidroside promotes the osteogenic and odontogenic differentiation of human dental pulp stem cells through the BMP signaling pathway | |
ES2032339T3 (es) | Procedimiento para preparar nuevos compuestos de indolilpiperidina. | |
MX172079B (es) | Produccion de trazolinonas | |
ES2029879T3 (es) | Procedimiento para producir derivados de aminas sustituidas. | |
FI905957A0 (fi) | Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet. | |
UY28647A1 (es) | Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos | |
ES2172023T3 (es) | Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |